– USA, MA – Cyteir Therapeutics, Inc. (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of John Thero to its board of directors, bringing the board directors from eight to nine members.
“John has valuable experience in helping emerging growth companies overcome challenges and create shareholder value. He has successfully developed and launched new products, most notably Amarin’s VASCEPA®, and entered various forms of strategic relationships with larger companies. As Cyteir grows, John’s insights and experience will be very helpful to Cyteir. On behalf of our entire board, we are excited to welcome John and look forward to his contributions” said CEO, Dr. Markus Renschler.
Mr. Thero will also join the audit committee as the Chair.
About John F. Thero
John Thero is an accomplished financial and operations executive with more than 30 years of experience in senior roles, including more than 20 years supporting the growth of life science companies. In 2019, Mr. Thero was named Ernst & Young LLP Entrepreneur of the Year for Life Sciences.
From 2009, until he was elected to retire in August 2021, Mr. Thero was an executive officer at Amarin Corporation PLC, including serving as President since 2010 and as CEO and a member of its board of directors since 2014. During his tenure at Amarin, he helped successfully lead the company through clinical development, global regulatory approvals, and the commercialization of VASCEPA. Before Amarin, Mr. Thero served as CFO at ViaCell, Inc., where he helped guide the company in its sale to PerkinElmer, and Abiomed, Inc., where he held multiple positions, including SVP of Business Operations and CFO. Mr. Thero began his professional career at Arthur Andersen LLP.
“I am excited to be joining the board of Cyteir Therapeutics as CYT-0851 advances and has the potential to become an important therapeutic option for oncology patients,” said John Thero. “I look forward to working with the other members of the board and Cyteir’s management team to help drive growth and execution at Cyteir.”
He received a B.A. in Economics and Accounting from The College of the Holy Cross in Worcester, Massachusetts. He is currently a member of the board of directors at CinCor Pharma, Inc.
About Cyteir Therapeutics, Inc.
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly-owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.
For more information: https://cyteir.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
